Hoth Therapeutics receives U.S. notice of allowance for Exon-skipping therapy

Hoth Therapeutics (HOTH) announced that the USPTO has issued a Notice of Allowance for “Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases.” The Notice of Allowance confirms that the USPTO has allowed all pending claims in the application, moving the patent toward formal issuance. This patent protects a novel dual-mechanism approach targeting key regulators of allergic and inflammatory responses. The allowed claims cover methods directed at: Exon skipping a critical component of the high-affinity IgE receptor pathway central to allergic disease activationless than modulation of MS4A6A, a gene associated with immune signaling and inflammatory regulation; combination therapeutic strategies designed to reduce hypersensitivity responses at a molecular level.